Premium
Linezolid Clearance During Continuous Venovenous Hemodiafiltration: A Case Report
Author(s) -
Kraft Michael D.,
Pasko Deborah A.,
DePestel Daryl D.,
Ellis Jessica J.,
Peloquin Charles A.,
Mueller Bruce A.
Publication year - 2003
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.23.8.1071.32874
Subject(s) - linezolid , medicine , anesthesia , anuria , critically ill , surgery , vancomycin , biology , bacteria , genetics , staphylococcus aureus
Objective. To determine the linezolid clearance and serum concentrations in a critically ill man receiving continuous venovenous hemodiafiltration (CVVHDF). Methods. Intravenous linezolid 600 mg every 12 hours was administered to a critically ill, 85‐year‐old man with anuria who was receiving CVVHDF at a dialysate flow rate of 2000 ml/hour and a mean ultrafiltrate production rate of 775 ml/hour. Samples of blood and spent dialysate and ultrafiltrate were obtained at the time of linezolid peaks and troughs, and linezolid concentrations were determined. Results. The CVVHDF yielded a mean linezolid clearance of 36.5 ml/minute and an elimination half‐life of 7.5 hours. The linezolid saturation coefficient ranged from 0.77–0.81. Administration of intravenous linezolid 600 mg every 12 hours yielded suitable serum trough concentrations. Conclusion. Administration of intravenous linezolid 600 mg every 12 hours maintained therapeutic serum trough concentrations in this critically ill patient receiving CVVHDF.